This study will investigate the safety and tolerability of AZD2115 following administration of multiple ascending doses.

A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Inhaled Doses of AZD2115 in Healthy Male Subjects.

Inclusion Criteria:

• Healthy male subjects aged 18 to 45 years with suitable veins for cannulation or repeated venepuncture
• Male subjects should be willing to use barrier contraception ie, condoms and spermicide, from the day of first administration of the AZD2115 until 3 months after administration and must not donate sperm for 3 months after follow-up
• Have a body mass index (BMI) between 18 and 30 kg/m2 and weigh at least 50 kg and no more than 100 kg

Exclusion Criteria:

• Abnormal vital signs, after 10 minutes supine rest, defined as any of the following:

  • Systolic BP >140 mmHg
  • Diastolic BP >90 mmHg
  • Heart rate <40 or >85 bpm

• Prolonged QTcF >450 ms or shortened QTcF <340 ms or family history of long QT syndrome

• Serum potassium concentration of < 3.80 mmol/L on admission (Day -1)

• History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with the same class to AZD2115 or to excipients

• History or presence of gastrointestinal, pulmonary, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs